

DECEMBER 2024 QUARTERLY ACTIVITY REPORT

HIGHLIGHTS

- Initiated IND-enabling studies for EmtinB's intravitreal administration, following a pre-IND meeting with the FDA
- Preliminary results from a melanin binding study have guided the selection of appropriate animal models for upcoming studies
- Cash balance of A\$4.5M at 31 December 2024

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) ("NeuroScientific" or "the Company") today submitted its Appendix 4C and quarterly activity report for the period ended 31 December 2024.

QUARTERLY ACTIVITY REPORT

Progression of IND-enabling studies in advanced glaucoma

Following a Pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in June, NeuroScientific has initiated a series study to prepare for its first-in-human clinical trials. These IND-enabling studies aim to evaluate the safety (toxicology), how the drug is processed in the body (pharmacokinetics), and the optimal formulation of EmtinB for administration directly into the eye (intravitreal administration).

To support these efforts, NeuroScientific engaged a leading global bioanalytical laboratory to conduct an *in vitro* melanin binding study. Preliminary results indicate that EmtinB binds strongly with melanin, a result that plays a key role in selecting the appropriate breed of rabbits for upcoming studies. Because different rabbit breeds have varying levels of melanin in their eyes, understanding this binding behaviour ensures the chosen animal models provide reliable data for predicting how the drug will behave in humans.

Building on the results of the melanin binding study, NeuroScientific is now preparing to advance toxicology and pharmacokinetics studies in animals. These studies are planned to begin in Q2 CY 2025 and conclude in early to mid Q3 CY 2025, bringing NeuroScientific closer to securing FDA approval for its first-in-human clinical trials.

New Opportunities

NeuroScientific has spent significant time evaluating a range of promising new opportunities to expand and enhance its existing portfolio. These endeavours are continuing.

Corporate

The Company held its Annual General Meeting of Shareholders on Wednesday 6 November 2024. All resolutions were passed.

Quarterly Cash Flow Summary

NeuroScientific's cash position was \$4.5 million as at 31 December 2024. The Company has maintained a strong cash position with expenses continuing to be carefully managed.

Research and development activity payments during the current quarter were \$21k (\$37k for the prior quarter ("PQ")). Staff costs for the quarter were \$83k (PQ - \$67k). Administration and corporate costs were \$192k (PQ - \$143k).

Payments to related parties during the December 2024 quarter totalled \$82k and relate to Director fees, salaries and superannuation.

The level of net cash burn for the March 2025 quarter is expected to be at similar levels as to the December 2024 quarter, as the Company continues to actively advance its IND-enabling studies for EmtinB in glaucoma, and begins to refine its, short-, medium- and long-term strategy.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Tony Keating
Executive Director
tony@neuroscientific.com
+61 8 6382 1805

Chris Ntoumenopoulos
Chair
ir@neuroscientific.com
+61 8 6382 1805

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

NeuroScientific Biopharmaceuticals Limited

ABN

13 102 832 995

Quarter ended ("current quarter")

31 December 2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(21)	(58)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(83)	(150)
(f) administration and corporate costs	(192)	(335)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	52	82
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(244)	(461)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,737	4,954
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(244)	(461)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	4,493	4,493

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,267	710
5.2	Call deposits	3,226	4,027
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,493	4,737

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(82)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>Item 6.1 above includes Director salaries, fees & superannuation (\$82k)</p>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(244)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,493
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,493
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	18.41
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: n/a	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: n/a	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: n/a	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 January 2025

Authorised by: The Board of Directors